Tel: 01789 267520

Latest News: Research

Updates on nusinersen/Spinraza Trials at the World Muscle Society Meeting

15 November 2017 / Posted in: Research

The 22nd International Annual Congress of the World Muscle Society (WMS) was held October 3rd-7th 2017 in Saint Malo, France. While SMA Support UK did not attend, Biogen have uploaded three posters to their repository that were presented at the meeting.

Read full story

Clinicians and Charities Make Further Appeal to NHS England to Widen Scope of SMA Type 1 Nusinersen EAP

30 October 2017 / Posted in: Research

SMA Support UK has backed the call led by Professor Francesco Muntoni not to limit the treatment only to infants with two SMN2 copy numbers.

Read full story

APPG Agrees Access To New Medicines For Rare Conditions Isn't Working

26 October 2017 / Posted in: Research

The All Party Parliamentary Group (APPG) on Rare, Genetic and Undiagnosed Conditions has asked Genetic Alliance UK to lead work to propose a solution.

Read full story

What Is Happening About Access To Nusinersen?

18 October 2017 / Posted in: Research

We share the frustrations of the SMA Community that there has still been no announcement from NICE about whether it will assess the treatment for continued and wider provision of nusinersen by the NHS. Here is an update of what SMA Support UK is doing.

Read full story

AveXis to Imminently Initiate AVXS-101 Pivotal Trial in the US

12 October 2017 / Posted in: Research

The Food and Drug Administration (FDA) has granted permission to AveXis to begin their planned US pivotal trial of their gene therapy drug for SMA, AVXS-101. Avexis say that they are to immediately begin the trial.

Read full story

Join MDUK's 'FastTrack' Campaign

11 October 2017 / Posted in: Research

Muscular Dystrophy UK are campaigning for faster access to specialist treatments, including Spinraza for SMA. You can find out more and support the 'FastTrack' Campaign here.

Read full story

NHS England replies to the joint clinicians/charities letter

29 September 2017 / Posted in: Research

The request to include those with more than two SMN2 copies and over 7 months of age in the SMA Type 1 nusinersen EAP is not yet successful. We are still waiting to hear from NICE about next steps.

Read full story

Novartis Releases Clinical Trial Update

27 September 2017 / Posted in: Research

Novartis has released the following community update for the LMI070 (branaplam) clinical trial.

Read full story

Roche’s SUNFISH study community update

19 September 2017 / Posted in: Research

Roche have provided an update on clinical trials of their SMN2 splice-modifying drug RG7916

Read full story

Revisiting the Consensus Statement for Standards of Care in SMA - Full Report

30 August 2017 / Posted in: Research

You can now read the full workshop report written by the clinical researchers and patient representatives from Europe and the US who met last year.

Read full story